ERBB2 and non-small cell lung carcinoma: HER2 non‐ex20ins mutations could potentially be considered positive predictors of ICI efficacy in advanced HER2‐mutated NSCLC patients, and ICI‐based therapy might be a good option for patients with HER2 non‐ex20ins mutations.